Scinai Immunotherapeutics Files 6-K Amendment
Ticker: SCNI · Form: 6-K · Filed: Sep 9, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, reporting, company-info
Related Tickers: SCIN
TL;DR
SCIN filed a 6-K amendment, confirming 20-F annual reports and former name BiondVax.
AI Summary
Scinai Immunotherapeutics Ltd. filed an amendment (Amendment No. 1) to its Report on Form 6-K on September 9, 2024. This filing is an update for the month of September 2024 and indicates the company files annual reports under Form 20-F. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name on June 24, 2014.
Why It Matters
This filing serves as an update for investors regarding Scinai Immunotherapeutics' reporting status and historical company information.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- September 9, 2024 (date) — Filing date of amendment
- 20240630 (date) — Conformed period of report
FAQ
What is the purpose of this filing?
This filing is an Amendment No. 1 to the Report on Form 6-K, originally filed, serving as an update for the month of September 2024.
What is the company's former name?
The company's former name was BiondVax Pharmaceuticals Ltd.
When did the company change its name?
The company changed its name on June 24, 2014.
Under which form does the registrant file annual reports?
The registrant files annual reports under cover of Form 20-F.
What is the principal executive office address?
The principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Filing Stats: 382 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-09-09 07:23:58
Filing Documents
- ea0212497-6k_scinai.htm (6-K) — 16KB
- ea021249701ex99-1_scinai.htm (EX-99.1) — 123KB
- ea021249701ex99-2_scinai.htm (EX-99.2) — 271KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- ex99-1_002.jpg (GRAPHIC) — 29KB
- 0001213900-24-076707.txt ( ) — 2509KB
- scni-20240630.xsd (EX-101.SCH) — 31KB
- scni-20240630_cal.xml (EX-101.CAL) — 23KB
- scni-20240630_def.xml (EX-101.DEF) — 123KB
- scni-20240630_lab.xml (EX-101.LAB) — 267KB
- scni-20240630_pre.xml (EX-101.PRE) — 130KB
- ea0212497-6k_scinai_htm.xml (XML) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: September 9, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2